Bruker Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
15.3%projected annual EPS growth
Analyst Coverage
12analysts covering
FY Revenue (est.)
$3.6Bnext fiscal year
FY EPS (est.)
$2.12next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 4 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Organic Revenue Growth Quarterly-440.0%Target: 1.0% to 2.0%
Non-GAAP Diluted EPS Quarterly0.3Target: $2.10 to $2.15
BSI Book-to-Bill Ratio Quarterly100.0%Target: > 100x%
Watch Items
- Foreign Exchange HeadwindsTrigger: USD strengthening beyond March 31, 2026 baseline ratesAction: Re-evaluate full-year non-GAAP EPS guidance of $2.10 to $2.15 which includes an estimated 8% FX headwind.
- U.S. Academic and Government DemandTrigger: Continued soft academic/government funding in the U.S. and EuropeAction: Adjust segment revenue projections for BSI BioSpin and CALID; implement further cost-saving measures.
Research as of 2 Sep 2026